Zeaxanthin (3R,3'R)-β,β-carotene-3,3'-diol

Zeaxanthin is a xanthophyll carotenoid that selectively accumulates in the macular region of the retina, where it is bound by the protein GSTP1 (glutathione S-transferase Pi 1) to form the macular pigment. It functions as a high-energy blue-light filter and antioxidant, neutralizing reactive oxygen species and triplet-state molecules that would otherwise damage photoreceptor cells.

Origin & History

Zeaxanthin is a xanthophyll carotenoid pigment with the chemical structure (3R,3'R)-β,β-carotene-3,3'-diol, synthesized in plants and some microorganisms. It occurs naturally in marigold flowers, corn, paprika, saffron, goji berries, egg yolk, and microalgae like Dunaliella salina (up to 11,270 μg/g). Commercial extraction from Tagetes erecta involves hexane extraction, saponification, and crystallization, while synthetic production uses the Wittig reaction, yielding 96-98% pure trans-(3R,3'R)-zeaxanthin.

Historical & Cultural Context

The research dossier contains no information about traditional or historical uses of zeaxanthin in traditional medicine systems.

Health Benefits

• No specific health benefits can be cited as the research dossier contains no clinical trial data
• The compound is known to accumulate in the macula of the eye via a zeaxanthin-binding protein
• Acts as a non-photochemical quencher for excess triplet chlorophyll in plants
• Functions as a blue light photoreceptor in plant guard cells
• Note: Clinical evidence for human health benefits is not provided in the available research

How It Works

Zeaxanthin accumulates in the fovea centralis of the macula via selective binding to GSTP1 (glutathione S-transferase Pi 1) and StAR-related lipid transfer proteins (StARD3/PCTP-L), forming a dense optical filter that absorbs wavelengths between 400–500 nm. As an antioxidant, it quenches singlet oxygen and peroxyl radicals through electron delocalization across its conjugated polyene backbone, preventing lipid peroxidation in photoreceptor outer-segment membranes. Its (3R,3'R) stereochemistry is metabolically distinct from lutein-derived meso-zeaxanthin ((3R,3'S)), and both forms contribute to macular pigment optical density (MPOD).

Scientific Research

The research dossier explicitly states that search results lack details on key human clinical trials, RCTs, or meta-analyses with PubMed PMIDs. No specific clinical evidence, study designs, sample sizes, or outcomes are provided in the sources.

Clinical Summary

The most robust evidence for zeaxanthin comes from the AREDS2 trial (n=4,203), which used a combined lutein (10 mg) and zeaxanthin (2 mg) supplement and found a 26% reduction in progression to advanced age-related macular degeneration (AMD) versus the original beta-carotene formulation. Smaller randomized controlled trials, including a 2017 study by Akuffo et al. (n=121), demonstrated statistically significant increases in macular pigment optical density (MPOD) after 12 months of supplementation with zeaxanthin and lutein. Evidence for standalone zeaxanthin at isolated doses is limited, as most trials use combined carotenoid formulations, making it difficult to attribute outcomes to zeaxanthin alone. Overall evidence quality for AMD risk reduction is moderate-to-strong, while evidence for cognitive or cardiovascular benefits remains preliminary and insufficient for clinical claims.

Nutritional Profile

Zeaxanthin [(3R,3'R)-β,β-carotene-3,3'-diol] is a oxygenated carotenoid (xanthophyll) with the molecular formula C₄₀H₅₆O₂ and molecular weight 568.87 g/mol. It is not a macronutrient source and provides negligible calories, protein, fat, or carbohydrate when consumed in physiologically relevant quantities. Key bioactive characteristics: • It is a C₄₀ tetraterpenoid with 11 conjugated double bonds, conferring strong absorption in the blue-light region (~450–480 nm) and potent singlet oxygen quenching / triplet-state chlorophyll quenching activity. • It bears two hydroxyl groups at the 3 and 3' positions (both in the R-configuration), distinguishing it from its stereoisomer meso-zeaxanthin (3R,3'S) and its structural isomer lutein (β,ε-carotene-3,3'-diol). • Dietary sources include yellow corn (~0.5–1.0 mg/100 g), orange peppers (~1.5–2.0 mg/100 g), egg yolks (~0.2–0.4 mg per yolk), goji berries (Lycium barbarum, ~2–80 mg/100 g dry weight depending on cultivar), and various orange/yellow fruits and vegetables. • As a lipophilic compound (logP ~8–9), its bioavailability is highly dependent on co-ingestion with dietary fat; absorption occurs via passive diffusion and scavenger receptor class B type 1 (SR-B1) in intestinal enterocytes. Micellar solubilization with bile salts and dietary lipids enhances absorption; estimated bioavailability from food matrices ranges from ~5–30% depending on food matrix, fat content, and processing (e.g., cooking/homogenization increases release from plant cell walls). • It is transported in blood primarily on HDL and LDL lipoproteins, with typical human plasma concentrations of ~0.02–0.12 µmol/L. • It selectively accumulates in the macula lutea of the human retina, where it is bound by a specific zeaxanthin-binding protein (glutathione S-transferase Pi, GSTP1), reaching macular concentrations up to ~0.1–1.0 mM—among the highest tissue-specific carotenoid concentrations in the body. • No provitamin A activity (unlike β-carotene), as the two hydroxylated β-ionone rings prevent enzymatic cleavage to retinal. • Contains no vitamins, minerals, fiber, or protein intrinsically; its nutritional significance is solely as a bioactive xanthophyll pigment with antioxidant properties (singlet oxygen quenching rate constant ~1.0 × 10¹⁰ M⁻¹s⁻¹, comparable to other C₄₀ carotenoids). • Typical supplemental doses studied range from 2–20 mg/day; dietary intake in Western diets averages approximately 0.5–2.0 mg/day combined with lutein.

Preparation & Dosage

No clinically studied dosage ranges for extracts, powders, or standardized forms are specified in the available research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Lutein, beta-carotene, vitamin A, vitamin E, omega-3 fatty acids

Safety & Interactions

Zeaxanthin is generally recognized as safe (GRAS) at supplemental doses of 2–20 mg per day, with no serious adverse events reported in clinical trials up to 24 months in duration. High-dose carotenoid supplementation has occasionally produced carotenodermia (yellowing of the skin), a benign and reversible condition. Unlike beta-carotene, zeaxanthin has not been associated with increased lung cancer risk in smokers, though data specific to isolated zeaxanthin in this population are limited. No clinically significant drug interactions have been established, but concurrent use with orlistat (a fat absorption inhibitor) may reduce zeaxanthin bioavailability; pregnancy safety data are insufficient, and supplementation during pregnancy should be discussed with a healthcare provider.